NCT07066150Completed
A Clinical Evaluation of Marula-Derived Ceramide Cream on Skin Barrier Function Enhancement
Efficacy of Marula Oil-Derived Ceramide Cream in Improving Skin Barrier Function: A Clinical Evaluation
Source: ClinicalTrials.gov · Last updated 15 Jul 2025
Brief summary (registry, in English)
Previously, the investigators have demonstrated in vitro the excellent efficacy of marula oil-derived ceramide NPs in enhancing skin barrier function. The investigators's findings show that marula oil-derived ceramide NPs not only significantly reduces levels of inflammatory cytokines but also promotes the expression of key proteins in skin barrier integrity. These results suggest that marula oil-derived ceramide NPs may offer a more effective therapeutic option for skin barrier-disrupted diseases. Therefore, the investigators aim to further investigate the repair function of marula oil-derived ceramide NPs on the human epidermal barrier through a clinical trial.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 19 Jun 2025
- Start date
- 6 Feb 2025
- Primary completion date
- 6 Mar 2025
- Lead sponsor
- Shanghai Chicmax Cosmetic Co., Ltd.
- Diseases
- Atopic dermatitis (eczema), Psoriasis
- NCT number
- NCT07066150
What you commit to
- Study type: Interventional
- Participants enrolled: 32
- From 6 Feb 2025 to the primary completion date, 6 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent participation in other clinical studies
- Cosmetic/drug use on assessment day
- Skin peeling/cosmetic procedures within 3 months prior to enrollment
- Immunosuppressant therapy within 3 months prior to enrollment
- Systemic steroid treatment or phototherapy within 1 month prior to enrollment
- Use of topical medications/special efficacy cosmetics on target area within 2 weeks prior to enrollment
Other illness
- Infectious skin diseases or atopic dermatitis
- History of severe reactions to cosmetics, drugs, or light exposure
Other
- Unwillingness to comply with protocol requirements
- Pregnancy or lactation (self-reported)
- Pharmacological treatment during study
- Skin abnormalities in assessment area (e.g., moles, telangiectasia)
- Assessment area lesions interfering with measurements
- Principal Investigator discretion of unsuitability
Who the study is looking for
- Healthy females aged 18 to 60 years
- Skin types: oily, combination oily, neutral, dry, or combination dry
- Ethnicity: Asian (Chinese)
- Sensitive skin confirmed by lactic acid stinging test screening
- Transepidermal water loss (TEWL) \> 15 g/h/m² in one cheek area
- Stratum corneum moisture content \<50 C.U. in one cheek area
- Visual redness score 3-6 per SGS standard atlas (0-9 scale, 0.5-point increment)
- Willingness to sign photo consent form
- No significant skin lesions, scars, or excessive facial/neck hair
- Ability to comply with protocol requirements and maintain consistent lifestyle
Age in the registry: 18 years to 60 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| SGS-CSTC Standards Technical Services (Qingdao) Co., Ltd. Coordinator of this site? Confirm its status | Qingdao | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.